Bridging stakeholders with biotechnology Accelerated path to human trials Growing knowledge base Ensuring dependability   BioViva is a ...

BioViva scientist Ali Fallah et al have worked on the reprogramming potential of GCS (germline derived stem cells) the self-renewal capac...

Aging is the root cause of the diseases of old age, and this disease burden causes an immense amount of suffering to individuals and soci...

BioViva scientist Ali Fallah and his team work on novel gene therapy using anti-inflammatory cytokines and show that these can be a promi...

Research by BioViva scientist Ali Fallah: ” In this study, we describe an efficient approach for stable knockdown of adenosine kinase (AD...

“Patient advocates are the driving force behind the development of many new drugs and amendments to medical regulations. It is the common...

In April 2016 BioViva USA Inc. published a press release stating that Elizabeth Parrish, CEO, had experienced telomere lengthening in her...

It has officially been one year since I volunteered to take the first gene therapy to treat biological aging. It has been an amazing year...

A precision-engineered gene therapy virus, inserted into blood stem cells that are then transplanted, markedly reduced sickle-induced red...